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Background: Ischemic postconditioning (IPostC), has been proposed as a useful approach to reduce infarct size in
all species, but its clinical utility remains unclear.
Objective: To investigate the role played by the protocol used on the efﬁcacy of IPostC in protecting the diseased
human myocardium.
Methods:Myocardial atrial samples from patients were subjected to a 90 min ischemia/120 min reoxygenation
followed by different IPostC protocols to investigate the role of the time of ischemia (30, 60, 90 and 120 s) and
the number of cycles (1, 2, 3 and 4) with 60 and 120 s of total ischemic time. Muscles were also subjected to is-
chemic preconditioning (IPreC). The release of lactate dehydrogenase (LDH) and the measurement of tetrazoli-
um bromide (MTT) were determined.
Results: IPostC increased the LDH and decreased the MTT values from those of control, independently of the
duration of the conditioning ischemia. LDH and MTT values also worsened by augmenting the number of IPostC
cycles whereas they were signiﬁcantly improved by IPreC. However, analysis of individual results indicated that
in approximately 1/3 of the cases IPostC exhibited some degree of protection especially in the presence of
increased ischemic injury.
Conclusions: The present ﬁndings show that IPostC of the humanmyocardiummay be inﬂuenced by the protocol
used and also by the degree of the preceding ischemic injury. IPostC was beneﬁcial in approximately 1/3 of the
cases; however in the remaining cases it increased ischemic damage and, therefore, these results raise a word
of caution on its broad clinical use.
© 2015 The Authors. Publishedby Elsevier Ireland Ltd. This is anopen access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Infarct size is recognized as amajor determinant ofmyocardial func-
tional recovery and mortality after an acute myocardial infarction [1].
Hence limitation of infarct size is critical to improve survival and to pre-
vent the development of heart failure. The most effective treatment to
reduce infarct size is the re-opening of the culprit occluded coronary ar-
tery by coronary angioplasty or thrombolysis. Adjunctive treatments at
reperfusion, such as β-blockers and angiotensin converting enzyme in-
hibitors, can ameliorate morbidity and mortality, although not via a re-
duction in infarct size [2]. Despite these improvements in treatment,
mortality remains elevated in high risk patients [3] and the prevalence
of heart failure is also increasing [4], which justiﬁes the search for ther-
apies that would effectively reduce infarct size.
It has been suggested that reperfusion injury accounts for 50% of the
ﬁnal size of amyocardial infarction [5] and that ischemic postconditioning34 93274 6052.
iñanes).
land Ltd. This is an open access article(IPostC), a sequence of short reperfusion/ischemia episodes after a
prolonged ischemic period, can be a useful approach to reduce infarct
size. The ﬁrst evidence of infarct size reduction associated with IPostC
was reported by Zhao et al. [6] in a caninemodel. Afterwards, experimen-
tal studies in variousmodels and species (dog, rabbit, mouse, rat and pig)
have conﬁrmed the beneﬁcial action of IPostC [7], although other studies
have reported no protection [8–10] or even a detrimental effect [11]. The
reason for this discrepancy could be due to the use of different IPostC pro-
tocols, variations on the duration of the ischemic insult, and even the an-
esthetic regimen, and the animal species and type of strain utilized [12].
Staat et al. [13] performed theﬁrst prospective clinical trial on the ef-
ﬁcacy of IPostC in patients with ST-segment elevation myocardial in-
farction (STEMI). In this study involving a small number of patients,
they showed a reduction in myocardial infarct size, as estimated by
the blood levels of creatine kinase. However, afterwards, small size ran-
domized trials [14] and, more recently, larger randomized studies
[15–17] have reported a lack of reproducibility of the IPostC response.
The source of disagreement is not clear but it is possible that the lack
of uniformity on the IPostC protocol between studies may play a role.under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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protect the ischemic and reoxygenated human myocardium, we used
a well characterized in vitro experimental model [18]. This model pro-
vides us a matchless opportunity to test cardioprotective strategies in
the humanmyocardium and to investigate the underlying mechanisms
in a safe, rapid and inexpensive manner.2. Materials and methods
2.1. Patients
The studywas approved by the local Ethics Committee and informed
consentwas obtained from all the participating patients. The right atrial
appendage was obtained from patients undergoing elective cardiac
surgery prior to cannulation of the heart and the establishment of car-
diopulmonary bypass. Demographic data, presence of vascular risk fac-
tors and medical treatment received for each participant patient were
recorded. A total of 150 patients (50 in each study) were sequentially
recruited without the exclusion criteria.2.2. Study groups
2.2.1. Study 1
2.2.1.1. Duration of the IPostC ischemic time. To study the role of the is-
chemia time in IPostC, the muscles obtained from the right atrial ap-
pendage were postconditioned with 30, 60, 90 and 120 s of total
ischemia and divided into 3 cycles of 10, 20, 30 and 40 s, of ische-
mia/reoxygenation (I/R) respectively (n = 50), following 90 min of
ischemia (Fig. 1).2.2.2. Study 2
2.2.2.1. Number of IPostC cycles. To investigate the role of the number of
cycles in IPostC, themuscles obtained from the right atrial appendage of
another 100 patients were postconditioned by 1, 2, 3 and 4 cycles of I/R
for a total of 60 (Study 2A; n = 50) and 120 s (Study 2B; n = 50) of is-
chemia after 90 min of ischemia (Fig. 2a & b).
In all the studies the IPostC stimulus was applied 30 s after the
90 min ischemic time, a period that has been shown to be necessary
to induce protection [19].Fig. 1. Experimental protocol for Study 1. All groups were equilibrated for 30–40 min at 37 °C i
120 min of ischemia/reoxygenation (I/R). Somemuscles did not undergo further treatment (I/R
vided in 3 cycles of 10, 20, 30 and 40 s or preconditioned (IPreC) with 5 min of ischemia and 5
entire experimental period.2.3. Experimental preparation
The right atrial appendages were collected in buffer Krebs Henseleit
Hepes (KHH) containing: 118mMNaCl, 4.8 mMKCl, 27.2 mMNaHCO3,
1.2mMMgCl2, 1.0mMKH2PO4, 1.25mMCaCl2, 10 mM glucose, 20mM
HEPES and pH 7.4 at 4–5 °C. Brieﬂy, the appendagewasmounted onto a
ground glass plate with the epicardial surface facing down and then
sliced using surgical skin graft blades (Swann-Morton, UK) to a thick-
ness of between 300–500 μm. The right atrial appendage and the slide
were always keptmoist throughout theprocedure. Themuscles (weight
30–50 mg) were then transferred to an Erlenmeyer (Trallero and
Schlee, Barcelona, Spain) containing 10 ml of oxygenated buffer KHH
(pH 7.4) and placed into a shaking water bath maintained at 37 °C.
For the induction of simulated ischemia, the buffer KHH was bubbled
with 95% N2–5% CO2 (pH 6.8–7.0) and D-glucose (Sigma, St. Louis,
MO) was removed and substituted with 2-deoxy-D-glucose (Sigma, St.
Louis, MO).
After sectioning the right atrial appendage, the muscles were equil-
ibrated for 30–40min. In all studies simulated ischemiawas induced for
a period of 90 min followed by 120 min of reoxygenation and then ran-
domly allocated to the various protocols of IPostC (see below). Some
muscles were aerobically incubated for an identical time period and
others were subjected to ischemic preconditioning (IPreC), induced by
a 5 min ischemia followed by a 5 min reoxygenation prior to the
90 min ischemia, a protocol shown to elicit optimal protection in this
preparation [18].2.4. Measurement of tissue injury and viability
Tissue injury was determined by measuring the leakage of lactate
dehydrogenase (LDH) into the incubation medium during the
120min of reoxygenation. An advanced kinetic, based on the formation
of NAD+ L-lactate which is directly proportional to the amount of LDH
activity used. The absorbance was measured at a 340-nm wavelength
with a MultiSkan FC spectrometer and the results, obtained after sub-
traction of the aerobic control values, were expressed as AU/g wet wt.
Tissue viability was assessed by the reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(Sigma, St. Louis, MO) to a blue formazan product in the muscles at
the end of the 120 min reoxygenation period. The absorbance of the
formazan formed was measured at a 550-nm wavelength with the
MultiSkan FC spectrometer and the results, obtained after subtraction
of the aerobic control values, were expressed as AU/g wet wt.n aerobic conditions. Muscles (n = 50) were subjected to 90 min of ischemia followed by
alone),others were postconditioned (IPostC) by 30, 60, 90 and 120 s of total ischemia di-
min of reoxygenation while others were maintained under aerobic conditions (AC) for the
Fig. 2. Experimental protocol for Study 2A. All groupswere equilibrated for 30–40min at 37 °C in aerobic conditions. Muscles (n=50/study)were subjected to 90min of ischemia follow-
ed by 120 min of ischemia/reoxygenation (I/R). Some muscles did not undergo further treatment (I/R alone), others were postconditioned (IPostC) with 1, 2, 3 and 4 cycles of ischemia/
reoxygenation for a total ischemic time of 60 s or preconditioned (IPreC)with 5min of ischemia and 5min of reoxygenationwhile others weremaintained under aerobic conditions (AC)
for the entire experimental period.
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Continuous variables were expressed as means ± S.E.M. and com-
pared using ANOVA followed by Dunnett's test; all IPostC protocols
were compared with I/R alone group. Linear regression and logistic bina-
ry regression were also used to compare the effect of co-morbid condi-
tions and medical treatments. A uni-variate analysis was performed to
study the effect of the concomitant cardiac pathologies, the associated
co-morbid conditions and themedical treatments received by themuscle
donors on IPostC. Statistical analyses were performed using the SPSS 20
andGraphPad Prisma 6. A pb 0.05was considered statistically signiﬁcant.
3. Results
Table 1. summarizes the demographic data, the associated clinical co-
morbid conditions and the type of heart disease suffered by the donors
of the right atrial appendages. Figs. 3, 4 and 5 show the mean values of
LDH leakage and MTT for all the groups in studies 1, 2A and 2B, respec-
tively. They show that in all the studies the LDH and MTT mean values
for the I/R alone groups (controls) were similar. They also demonstrate
that IPreC was beneﬁcial in the three studies, with signiﬁcant reduction
in LDH leakage and improvement in MTT when compared to I/R alone.3.1. Effect of the IPostC ischemic time
Fig. 3a & b show that all the investigated ischemic time durations for
IPostCwere detrimental to a similar degree (Study 1), with a signiﬁcant
increase in LDH leakage and decrease in the MTT mean values in all the
groups compared to I/R alone.
3.2. Effect of the number of IPostC cycles
Fig. 4a & b show that the number of IPostC cycles with a total of 60 s
of ischemia (Study 2A) was also detrimental (mean values for LDH in-
creased and MTT decreased) compared to I/R alone; 1 cycle was the
least deleterious and 4 cycles were the most harmful. As shown in
Fig. 5a & b, an identical pattern was observed with 120 s of total ische-
mia (Study 2B), with a clear tendency to augment myocardial damage
when the number of cycles increased.
Analysis of the individual results for all the studies (see Fig. 6) re-
vealed that, in some of the studies, IPostC exhibited a weak but statisti-
cally signiﬁcant relationship for LDH and for MTT when the difference
between IPostC and its corresponding I/R alone value on one side was
compared with I/R alone on the other, suggesting that IPostC is more
beneﬁcial with severe degrees of ischemic injury. Thus, even though
Table 1
Demographic data.
Study 1 Study 2A Study 2B
Sex (F/M) 31/19 18/32 15/35
Age 65 ± 3 70 ± 10 63 ± 14
Obesity 26 (52%) 29 (58%) 24 (48%)
Diabetes 12 (52%) 28 (56%) 13 (26%)
Insulin-dependent 4 (8%) 8 (16%) 6 (12%)
Non insulin-dependent 7 (14%) 20(40%) 7 (14%)
Dyslipidemia 21 (42%) 37 (74%) 30 (60%)
Hypertension 30 (60%) 36 (72%) 37(74%)
CAD 18 (36%) 22 (44%) 15 (30%)
AAA 3 (26%) 8 (16%) 12 (24%)
Congenital disease 6 (12%) 1 (2%) 12 (24%)
LVEF
N40% 49 (100%) 42 (84%) 43 (86%)
b40% 0 (0%) 8 (16%) 7 (14%)
AF
Paroxistic 4 (8%) 5 (10%) 1 (2%)
Permanent 13 (26%) 4 (8%) 6 (12%)
AVD 30 (60%) 32 (64%) 28 (56%)
MVD 13 (26%) 4 (8%) 14 (28%)
TVD 7 (14%) 2 (45%) 2 (4%)
AAA, ascending aortic aneurism; AF, atrial ﬁbrillation; AVD, arterial vascular disease; CAD,
coronary artery disease; LVEF, left ventricle ejection fraction; MVD, mitral valve disease
and TVD, tricuspid valve disease for all the groups (n = 50/study).
Fig. 4. The effect of the numbers of cycles (1, 2, 3 and 4 cycles) used in IPostC with a total
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in all three studies, approximately in 1/3 of the cases IPostC exhibited
some degree of beneﬁt.
A uni-variate analysis did not show a signiﬁcant beneﬁcial neither
detrimental effect of the concomitant cardiac pathologies, the associat-
ed co-morbid conditions and the medical treatments received by the
muscle donors on the effect of IPostC (data not shown).Fig. 3. The effect of the ischemic time (30,60, 90 and 120 s) in IPost on the (a) LDH leakage
and (b) MTT reduction of muscles (n = 50/group) subjected to 90 min of ischemia
followed by 120 min of reoxygenation. The resulst were obtained after substraction of
the aerobic control values. *p b 0.05 vs I/R alone group and †p b 0.05 vs all IPostC groups.
ischemia of 60 s on the (A) LDH leakage and (B)MTT reduction ofmuscles (n=50/group)
subjected to 90 min of ischemia followed by 120 min of reoxygenation. The results were
obtained after substraction of the aerobic control values. *p b 0.05 vs I/R alone group
and †p b 0.05 vs all IPostC groups.4. Discussion
This is the ﬁrst study to investigate themost effective IPostC protocol
in the human myocardium. This information cannot be obtained from
in vivo studies and we took advantage of a well characterized in vitro
model to carry out the investigation. The results demonstrate that
IPostC can be harmful to the human myocardium, although in approxi-
mately 1/3 of the cases exhibited some degree of beneﬁt. The effect of
IPostC is independent on the duration of the postconditioning ischemic
times used but it shows a tendency to augment myocardial damage
when the number of cycles was increased. These ﬁndings are of clinical
importance and they warrant further discussion.
A previous reviewof the literature ZhouC et al. [20], and also themost
recent randomized clinical trials [15–17], show a lack of uniformity on
the IPostC protocol used, with different interval times used for the brief
periods of ischemia and also reperfusion. The majority of these studies
used 3 or 4 cycles of ischemia/reperfusion that in the present investiga-
tionswe found to bemore detrimental than1or 2 cycles. Indeed, this het-
erogeneity without deﬁnition as to which is the most effective IPostC
protocol makes difﬁcult the comparison among studies and the under-
standing on the real clinical utility of the intervention. The NHLBI Work-
shop that resulted in the formation of the CAESAR (NIH Cardioprotection
Consortium), stated: “Only treatments providing consistent and robust ben-
eﬁt in pre-clinical studies involving different models and laboratories should
be considered. Although this may seem an obvious pre-requisite, the failure
to take this factor into consideration has led to a large number of negative
clinical trials.” As a result, this consortium has created a network of re-
search laboratories, which are using a variety of clinically relevant pre-
clinical animal myocardial infarction models, to test the efﬁcacy of
novel therapeutic agents to ensure that they confer consistent and robust
Fig. 5. The effect of the numbers of cycles (1, 2, 3 and 4 cycles) in IPostC with a total ische-
mia of 120 s on the (A) LDH leakage and (B) MTT reduction of muscles (n = 50/group)
subjected to 90 min of ischemia followed by 120 min of reoxygenation. The result were
obtained after substraction of the aerobic control values. *p b 0.05 vs I/R alone group
and †p b 0.05 vs all IPostC groups.
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studies were performed in line with this vision and the ﬁndings suggest
that IPostC may be harmful to patients with cardiac diseases and that,
therefore, no further clinical trials should be carried out until issues like
themost effective IPostC protocol and the role of the degree of preceding
ischemic injury are fully elucidated in pre-clinical investigations.
A number of potential explanations for the failure of IPostC to induce
cardioprotection have been put forward [23,24]. One could be the
existing variability in age and sex, the associated comorbidities and the
treatment with different medications [25]. Animal studies have shown
that the beneﬁcial properties of IPostC are lost with advanced age [26,
27] and that the effect is smaller in females [28]. Also, a meta-analysis
from randomized controls trials has suggested that the beneﬁcial effect
of IPostC is more pronounced in young and male patients [20], although
other investigators have reported a more pronounced protection in
women [29]. In the present studieswedidnot demonstrate a relationship
of IPostC with age, sex or any of the other clinical conditions andmedical
treatments that have been considered to be confounding factors [30].
The duration of acutemyocardial ischemia is a major determinant of
the ﬁnal myocardial infarction size and has been proposed as another
factor that could inﬂuence IPostC. On the one hand, a pre-clinical
study has reported that IPostC can be detrimental with short periods
of ischemia [11] but so far there is no evidence that IPostC may be ben-
eﬁcialwith longer ischemic times. However, on the other hand, it is pos-
sible to argue that with severe ischemia there could be little salvageable
myocardium left, so that the protective effect of any interventionmight
be too small to measure. In the context of an acute coronary syndrome,
and due to the uncertainty over the beginning of the ischemia and thedegree of collateral ﬂow and severity of the ischemic insult, it would
be difﬁcult to clarify this point. In our studies the period of ischemia
was ﬁxed (90 min) and collateral ﬂow was not a confounding factor
and, therefore, the issue of the severity of the ischemic insult should
not be a relevant factor to explain the lack of efﬁcacy of IPostC. Yet, in
this setting, the response to ischemia greatly differed among patients
and the relationships seen between the degree of ischemic myocardial
damage and postconditioning (Fig. 6) suggest that IPostC tends to be
more beneﬁcialwith themore severe degrees of ischemic injury. A com-
plete clariﬁcation of this issue would require additional studies.
In contrast to the results on IPostC, our studies have consistently
shown beneﬁt by IPreC, thus suggesting that the mechanism of protec-
tion of the two interventions could be mediated by different mecha-
nisms. However, a number of laboratories have shown that IPostC and
IPreCmay share some commonpathways [31,32] albeit theymay exhib-
it some differences in the mechanism and level of protection [9,33]. If
IPostC and IPreC possess some distinctive mechanisms of protection, it
could be argued that the combined application of the two interventions
could induce amore efﬁcient protection. Nonetheless, the validity of this
argument could be challenged, since it has been reported in the skeletal
muscle of rats subjected to ischemia and reperfusion that the combina-
tion of IPreC and IPostC reduced glycogen depletion to a degree similar
to that of IPreC alone whilst IPostC alone did not show protection [34].
Other investigators have observed a loss of protection in the human
right atrial myocardium with the co-application of IPreC and IPostC
[35]. Differences in the protocol and the animalmodel usedmay explain
the discrepancy between these results but, certainly, this is an area of
great clinical interest that would require further investigations.
A potential limitation of our studies is the use of atrial tissue as that
may not fully represent the response of ventricular myocardium. How-
ever, we [36] and others [37] have observed that the right atrial and left
ventricularmyocardium have similar tolerance to ischemia and compa-
rable response to protective interventions as IPreC. Another limitation
could be that they were performed in in vitro isolatedmyocardial tissue
and, therefore, caution must be taken when extrapolating the present
results to clinical conditions. Nonetheless, the laboratory model used
in this study provides us amatchless opportunity to test and reﬁne pro-
tective interventions in the human myocardium in a safe, rapid and in-
expensive manner before they are considered for clinical use.
5. Conclusions
The present ﬁndings have important implications and raise a note of
caution on the clinical utility of IPostC to reduce myocardial injury fol-
lowing a period of ischemia. They have demonstrated that although
IPostC induces some degree of beneﬁt in 1/3 of the cases it can be harm-
ful. The effect of IPostC may depend to certain extent on the protocol
used and on the degree of injury of the preceding ischemia. Therefore,
it is advisable that these issues are fully clariﬁed before further clinical
trials are carried out.
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Fig. 6. Correlation between I/R alone and the difference between IPostC and I/R alone for all the LDH andMTT values in Study 1(a1 & b1) and 2A(a2 & b2) and 2B(a3 & b3); n= 50/study.
*p b 0.05.
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